Bragging rights

Houston deemed one of the top 'Cities of the Future' in North America

"The Houston of today looks like the United States of tomorrow," says Susan Davenport, senior vice president of economic development at the Greater Houston Partnership. Photo by Zview/Getty Images

Watch out, world. Here comes Houston.

Houston ranks fifth on a new 2019-20 list of the 10 North American Cities of the Future produced by the fDi Intelligence division of the Financial Times. New York grabbed the No. 1 spot, followed by San Francisco, Toronto, and Montreal. Following Houston were Chicago; Boston; Los Angeles; Palo Alto, California; and Seattle.

The ranking is based on data in five categories:

  • Economic potential
  • Business friendliness
  • Human capital and lifestyle
  • Cost effectiveness
  • Connectivity

Susan Davenport, senior vice president of economic development at the Greater Houston Partnership, says Houston's "ethnically and culturally diverse population" coupled with its "robust and globally connected economy" help form a solid foundation for the city's future.

The North American Cities of the Future ranking is certainly not the only such accolade that Houston has garnered. Hailing Houston as "the American city of the future," Resonance Consultancy, a consulting firm, ranks Houston the 11th best large city in the U.S.

"Positive rankings and recognition like this help us continue to attract the best and brightest minds both domestically and around the world," Davenport says. "Houston has long been a place that solves the world's most complicated problems — from putting humans on the moon to pioneering open-heart surgery. But we make a conscious choice to measure ourselves not on past accomplishments but on what we do next."

Davenport cites Houston's vibrant startup scene, 21 Fortune 500 companies, and burgeoning innovation corridor, along with the presence of the world's largest medical complex, as helping position the city for economic growth.

She also mentions the fact that nearly one-fourth of local residents are foreign-born and that more than 145 languages are spoken. In April 2019, personal finance website WalletHub named Houston the most diverse city in the U.S.

"In short, the Houston of today looks like the United States of tomorrow," Davenport says.

In a March 2019 report, the Center for Houston's Future noted that Houston's economic growth — namely in the construction, healthcare and IT sectors — depends heavily on the continued influx of immigrants. Immigrants already make up nearly one-third of the region's workforce, the report says.

Between 2016 and 2036, almost 60 percent of all jobs added in the region will be filled by foreign-born workers, the report indicates.

Also on the international front, more than 5,000 Houston companies do business abroad, Davenport says, and more than 500 foreign-owned companies have invested in Houston in the past decade.

As Houston looks toward the future, business leaders will continue to diversify the economy through such sectors as life sciences, advanced manufacturing, and technology, according to Davenport. In addition, business leaders will keep driving the transition from traditional fossil fuels to "new energy" sources (like wind and solar), she says.

"Houston's future is a bright one," Davenport says. "Our young and well-educated workforce, coupled with targeted infrastructure investments, will help us become a hub for innovation in the years ahead."

Business Facilities magazine agrees with that assessment. In July 2018, it ranked Houston the No. 1 metro area for economic growth potential, stressing that the region's economy has expanded beyond Big Oil and that it's brimming with "innovation, technology, and entrepreneurship."

"Houston has a distinctly favorable business climate. The region benefits from a skilled workforce, world-class infrastructure and transportation system, and a pro-business environment that stimulates rather than stifles business growth," the magazine says.

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted